A randomized, double-blind, placebo-controlled, phase IIB study of the safety and efficacy of OVAREX MabB43.13 [oregovomab] in ovarian cancer patients with an elevated serum CA 125 but without other evidence of disease

Trial Profile

A randomized, double-blind, placebo-controlled, phase IIB study of the safety and efficacy of OVAREX MabB43.13 [oregovomab] in ovarian cancer patients with an elevated serum CA 125 but without other evidence of disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2011

At a glance

  • Drugs Oregovomab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top